●临床试验的优化设计和联合疗法的应用会改善白血病的治疗。35年前,伊莱休·艾斯特(Elihu Estey)还是得克萨斯州休斯敦安德森癌症中心的一名工作人员,他阅读了大量针对急性髓细胞白血病研发的临床试验药物的方案。他最感兴趣的是“基本原理”部分,解释各种疗法的治疗原理。“它们听起来都挺吸引人的。”艾斯特说,他现在在西雅图,是华盛顿大学的一名血液病专家,“但是,当然,能最后起到作用的非常少。”从那之后,研究者们已经在不同类型的白血病治疗方面取得了突飞猛进的进展,但是,会使白细胞前体细胞也就是骨髓细胞疯狂增加的恶性血液癌 ● The optimal design of clinical trials and the use of combination therapy will improve the treatment of leukemia. Thirty-five years ago, Elihu Estey, a staff member at the Anderson Cancer Center in Houston, Texas, read a large number of clinical trials of drugs developed for acute myeloid leukemia. He is most interested in the “Fundamentals” section, explaining the treatment principles of various therapies. “They sound very attractive.” Esther said he is now a Seattle-based hematology specialist at Washington University. “But, of course, there are very few things that will eventually make a difference.” Since then, researchers have made tremendous advances in the treatment of different types of leukemia, however, but they also make leukocyte precursors that are hematopoietic malignancies with increased myelocytosis